StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Kush Bohra

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byKush BohraHorizon: NA (inferred Swing (≤2wk))10 Aug 2026via NDTV Profit (Live)

Entry₹2,005Inferred
Target₹2,135
Total upside +6.48% (call closed)
Stop loss₹1,915-4.49% risk
Exit₹1,91517 Aug 2026, 9:15 am
Stop-loss hit-4.49%
Follow Kush Bohra for new calls(32% target hit, 188 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 152 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Aug 2026
4 supporting1 neutral0 opposing
Supports the BUY call (4)

Emcure Pharma receives USFDA EIR for Sanand facility; regulator classifies it as 'VAI'; here's what it means

NewsCnbc-Tv18·8 Aug · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Q1 Results: Net profit rises 42%, international business aids topline growth

NewsCnbc-Tv18·6 Aug · 1w ago

(opens in new tab)

Emcure Pharma Q1: Net Profit Jumps 42%; CEO Satish Mehta Appointed As Chairman

NewsNdtv-Profit·6 Aug · 1w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·8 Jul · 1mo ago

Neutral / worth noting (1)

Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·6 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Kush Bohra

Every call and its outcome